All the news Showing 10 of 31 articles from: Deciding when and how to treat HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough Liz Highleyman / 13 May 2015 A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver ... Another study confirms detrimental effects of delaying hepatitis C treatment Liz Highleyman / 05 May 2015 Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to ... Is There Any Good Reason Left to Delay Hepatitis C Treatment? Poz / 17 April 2015 Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... One million people with hepatitis C in the US at high priority for treatment Liz Highleyman / 07 January 2015 An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented ... PCORI Board Approves Providing Up to $50 Million for Research on Hepatitis C Treatment Comparisons Patient Centered Outcomes Research Institute / 10 December 2014 Low uptake of HCV treatment in England will lead to substantial disease burden by 2035 Michael Carter / 24 June 2014 Only 3% of people with chronic hepatitis C virus (HCV) are treated for their infection each year in England, according to research published in the Journal of Hepatology. The current uptake of ... Model shows that HCV therapy for patients with more severe fibrosis cost-effective in Egypt Michael Carter / 24 February 2014 Lack of resources means that Egypt should prioritise hepatitis C virus (HCV) treatment for patients with more advanced disease, according to a mathematical model published in the online edition of Clinical Infectious Diseases. Therapy ... Deferral of treatment in HCV patients: Risks and benefits Hepatitis B & C Public Policy Association / 17 February 2014 Express Scripts Pushes Price Competition for Gilead Drug Bloomberg / 11 December 2013 ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive